Leuprorelin
亮丙瑞林
Report date: 2026/04/24 20:01:59
Base Information
Drug NameLeuprorelin
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[7]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[11]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A
Develop Information
Active CompaniesUniversity Medical Center GroningenNational Cancer InstituteRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine +[4]
Inactive CompaniesForesee Pharmaceuticals Co LtdChong Kun Dang Pharmaceutical CorpChangchun GeneScience Pharmaceuticals Co Ltd
Active Indications +[5]
Inactive Indications
Other Information
ATC Code
Related LinksN/A